- Sun Pharma has recalled 10 eye drop brands in India due to contamination concerns, as stated in a letter to distributors on July 17.
- The letter instructed distributors to cease billing and return all stock of affected products, including Depopred, Brinolar, and Brinzotim.
- Patient safety is emphasized as the highest priority by a Sun Pharma spokesperson, who mentioned that teams are working to restore product availability.
- Experts have warned that many of these eye drops are used for post-surgery recovery or managing chronic conditions like glaucoma, and that treatment interruptions can have serious consequences.
- The recall has raised concerns about pharmaceutical safety standards, with experts noting that unsafe eye drops can lead to infections and potential vision damage.
- Maintaining sterility during manufacturing is critical, as contamination can pose serious risks to patient safety, making immediate recalls essential.
- Experts advise that patients should not use recalled products and should consult their ophthalmologist for alternatives to ensure continuity of care.
Sun Pharma Distributors Ltd has initiated a recall of 10 eye drop brands, including Brinolar and Lotepred, due to contamination concerns, as detailed in a letter to distributors dated July 17. The company instructed distributors to cease billing and return all existing stocks of the affected products.12
The letter specified the recalled products, which include Depopred2ML, Brinzotim Eye Drops 5ML, and Nepalact OD Eye Drops 3ML. Sun Pharma stated, “Patient safety remains our highest priority. We have taken all necessary steps in the best interest of patients and in accordance with applicable regulatory requirements.”3
Experts have raised alarms about the health risks associated with contaminated eye drops, which can lead to serious infections and potential vision damage. One expert noted, “In a country like India, where millions rely on eye drops every day, maintaining sterility during manufacturing is non-negotiable.” They emphasized that even suspected contamination can pose a serious risk to patient safety, necessitating immediate recalls.56
The recall has heightened scrutiny over pharmaceutical safety standards, with authorities stressing the need for consistent monitoring and improved manufacturing processes. Patients are advised not to use recalled products and to consult their ophthalmologists for alternatives to ensure continuity of care.7
Sun Pharma's recall reflects a growing concern over the safety and quality of ophthalmic medicines, as the company works to restore product availability while prioritizing patient safety.
“Sun Pharma Distributors Ltd's July 17 letter asked distributors to immediately cease billing and return stock of products including Depopred, Brinolar, Brinzotim, Lotepred, Nepalact OD, Nepalact-Z and Toba-F. Experts warn many are prescribed after eye surgery or for glaucoma and infections, so interrupting treatment can have significant consequences.”
livemint.com
